HealthDay News – Abaloparatide, a parathyroid hormone-related peptide, was shown to effectively reduce risk of new vertebral fractures in postmenopausal women with osteoporosis. These findings were recently published in the Journal of the American Medical Association.
Paul D. Miller, MD, of the Colorado Center for Bone Research in Lakewood, and colleagues randomly assigned 2,463 postmenopausal women with osteoporosis to receive daily injections of abaloparatide, teriparatide, or a placebo for 18 months (ClinicalTrials.gov Identifier NCT01343004). Their average age was 69.
The researchers found that among the 1,901 women who completed the trial, increases in bone mineral density were greater with abaloparatide than placebo. Fewer women on the injectable drug abaloparatide had vertebral fractures (0.58%) than women receiving a placebo (4.22%), and slightly fewer than those taking teriparatide (0.84%).
Women taking abaloparatide also had fewer other types of fractures (2.7%) than those who got a placebo (4.7%), and slightly fewer than those on teriparatide (3.3%). Fewer cases of hypercalcemia occurred among women taking abaloparatide (3.4%) than teriparatide (6.4%).
“The way forward for fracture prevention involves not only the development of better therapies to prevent fracture and easier delivery systems, but also improved adoption of existing osteoporosis therapies for patients with prior fractures and minimization of adverse effects, particularly those associated with long-term use,” write the authors of an accompanying editorial.
The study was funded Radius Health, the manufacturer of abaloparatide.
- Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA. 2016;316(7):722-733.
- Cappola AR, Shoback DM. Osteoporosis therapy in postmenopausal women with high risk of fracture. JAMA. 2016;316(7):715-716. doi:10.1001/jama.2016.11032.